Yota Yasumizu

Assistant professor

Keio University School of Medicine
Country flagJapan
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (9)

Targeting MUC1-C suppresses SCLC tumorigenicity. A, Six-week old nude mice were injected subcutaneously in the flank with 1 × 10 6 H69/tet-MUC1shRNA cells. Mice were pair-matched into two groups when tumors reached 100 to 150 mm 3 and were fed without and with DOX. Tumor volumes are expressed as the mean ± SD for 6 mice. B, Lysates from two untreated and two DOX-treated H69/tet-MUC1shRNA tumors obtained on day 21 were immunoblotted with antibodies against the indicated proteins. C, Six-week-old nude mice were injected subcutaneously in the flank with 1 × 10 6 H69/CsgRNA and H69/MUC1sgRNA cells. Tumor volumes are expressed as the mean ± SD for 6 mice. D, Six-week-old nude mice were injected subcutaneously in the flank with 1 × 106 H69/CsgRNA and H69/NOTCH2sgRNA cells. Tumor volumes are expressed as the mean ± SD for 6 mice. E, Lysates from two H69/CsgRNA and two H69/NOTCH2sgRNA tumors obtained on day 18 were immunoblotted with antibodies against the indicated proteins. F and G, Six-week-old nude mice were injected subcutaneously in the flank with 3 × 10 6 COR-L279 cells. Mice pair-matched into two groups when tumors reached 100 to 150 mm 3 were treated intraperitoneally each day with PBS or GO-203 for 19 days. Tumor volumes are expressed as the mean ± SEM for 6 mice ( F ). Lysates from tumors harvested on day 19 were immunoblotted with antibodies against the indicated proteins ( G ).

Year:

2025

MUC1-C is necessary for SCLC cell self-renewal. A and B, Representative images of tumorspheres derived from H69/tet-MUC1shRNA ( A ) and DMS53/tet-MUC1shRNA ( B ) cells treated with control vehicle or DOX for 7 days (left). Bar represents 50 μm. The number of tumorspheres is expressed as the mean ± SD of three determinations (right). C, Lysates from H69 (left) and DMS53 (right) cells expressing a CsgRNA or NOTCH2sgRNA were immunoblotted with antibodies against the indicated proteins. D, Representative images of tumorspheres derived from DMS53/CshRNA and DMS53/NOTCH2shRNA cells (left). Bar represents 50 μm. The number of tumorspheres is expressed as the mean ± SD of three determinations (right). E, Representative images of tumorspheres derived from COR-L279/tet-MUC1shRNA cells treated with control vehicle or DOX for 7 days (left). Bar represents 50 μm. The number of tumorspheres is expressed as the mean ± SD of three determinations (right). F, DMS53 cells treated with control vehicle or 5 μmol/L GO-203 for 3 days were seeded in dishes for 12 days. Representative images are shown for colonies stained with crystal violet (left). The number of colonies is expressed as the mean ± SD of three determinations (right). G and H, Representative images of tumorspheres derived from COR-L279 ( G ) and H526 ( H ) cells treated with control vehicle or 5 μmol/L GO-203 for 7 days (left). Bar represents 50 μm. The number of tumorspheres is expressed as the mean ± SD of three determinations (right).

Year:

2025

Expression of MUC1 in SCLC tumor tissues. A, Analysis of the GSE60052 SCLC bulk RNA-seq dataset demonstrating significant correlations of MUC1 with MYC and NOTCH2 expression in SCLC tumor tissues. B, Analysis of the GSE138267 SCLC scRNA-seq dataset demonstrating MUC1 expression in clusters of SCLC cells obtained from seven patient-derived CDX models. C, Distribution of MUC1 expression in the seven CDX models. D, Significant associations of MUC1 expression with activation of the HALLMARK MYC TARGETS V1 pathway in individual tumors. E, Representative IHC staining of MUC1-C expression in SCLC tumor tissue. Bar represents 50 μm. F, Proposed model for MUC1-C in driving SCLC progression. MUC1-C activates MYC and E2F target genes that contribute to the RSR and mitotic progression. MUC1-C→MYC signaling also drives expression of NOTCH2 and NE dedifferentiation. MUC1-C thereby integrates activation of the dysregulated MYC and E2F pathways and RSR with NE dedifferentiation, stemness, and self-renewal in SCLC cells.

Year:

2025

MUC1-C regulates common transcriptomes in SCLC-A cells. A, Lysates from H69 and DMS53 cells were immunoblotted with antibodies against the indicated proteins. B and C . H69 ( B ) and DMS53 ( C ) cells expressing a tet-CshRNA or a tet-MUC1shRNA were treated with vehicle or 500 ng/mL DOX for 7 days. The cells were analyzed for MUC1-C mRNA levels by qRT-PCR using primers listed in Supplementary Table S1. The results (mean ± SD of four determinations) are expressed as relative mRNA levels compared with that obtained for vehicle-treated cells (assigned a value of 1; left). Lysates were immunoblotted with antibodies against the indicated proteins (right). D, RNA-seq was performed in triplicate on H69/tet-MUC1shRNA and DMS53/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days. The datasets were analyzed for effects of MUC1-C silencing on repressed and activated genes as depicted by the Volcano plots. E, Overlap of down- and upregulated genes in H69 and DMS53 cells with MUC1-C silencing. F, RNA-seq datasets from H69 (left) and DMS53 (right) cells were analyzed with GSEA for enrichment distribution using the indicated BENPORATH collection gene signatures. G, RNA-seq datasets from H69 (left) and DMS53 (right) cells were analyzed with GSEA using the BENPORATH MYC TARGETS WITH EBOX gene signatures.

Year:

2025

Targeting MUC1-C suppresses ASCL1, NEUROD1, and YAP1 expression. A, Lysates from H69/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. B, Lysates from H69/CsgRNA, H69/MUC1sgRNA#1, and H69/MUC1sgRNA#2 cells were immunoblotted with antibodies against the indicated proteins. C, Lysates from DMS53/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. D and E, Lysates from H69/tet-MYCshRNA ( D ) and DMS53/tet-MYCshRNA ( E ) cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins. F and G, Lysates from COR-L279/tet-MUC1shRNA ( F ) and H526/tet-MUC1shRNA ( G ) cells treated with vehicle or DOX for 7 days were immunoblotted with antibodies against the indicated proteins.

Year:

2025

MUC1-C regulates common and distinct transcriptomes in NE and non-NE SCLC subtypes. A, Lysates from COR-L279 and H526 cells were immunoblotted with antibodies against the indicated proteins. B and C . COR-L279 ( B ) and H526 ( C ) cells expressing a tet-CshRNA or a tet-MUC1shRNA were treated with vehicle or 500 ng/mL DOX for 7 days. The cells were analyzed for MUC1-C mRNA levels by qRT-PCR. The results (mean ± SD of four determinations) are expressed as relative mRNA levels compared with that obtained for vehicle-treated cells (assigned a value of 1; left). Lysates were immunoblotted with antibodies against the indicated proteins (right). D and E. RNA-seq analysis was performed in triplicate on COR-L279/tet-MUC1shRNA and H526/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days. Common DEGs downregulated ( D ) and upregulated ( E ) by MUC1-C silencing in the indicated SCLC cells. The lollipop plots show common numbers of DEGs in the four different SCLC cells. F, RNA-seq datasets from the indicated cells were analyzed with GSEA using the BENPORATH MYC TARGETS WITH EBOX. G, The designated SCLC cells expressing a tet-MUC1shRNA were treated with vehicle of DOX for 7 days. Lysates were immunoblotted with antibodies against the indicated proteins.

Year:

2025

MUC1-C activates NOTCH2 expression by a MYC-mediated mechanism. A, Schema of the NOTCH2 promoter and enhancer regions with locations of potential E-boxes. B and C . Soluble chromatin from H69 cells was precipitated with anti-MUC1-C, anti-MYC, or a control IgG ( B ). Soluble chromatin was precipitated with anti-MUC1-C (ChIP) and then reprecipitated with anti-MYC or a control IgG (re-ChIP; C ). The DNA samples were amplified by qPCR with primers for the NOTCH2 promoter and enhancer regions. D, Soluble chromatin from H69/tet-MUC1shRNA cells treated with vehicle or DOX for 7 days was precipitated with anti-MYC or a control IgG. The DNA samples were amplified by qPCR with primers for the NOTCH2 promoter region. The results (mean ± SD of three determinations) are expressed as the relative fold enrichment compared with that obtained with the IgG control (assigned a value of 1). E, H69/tet-MUC1shRNA (left) and DMS53/tet-MUC1shRNA (right) cells treated with vehicle or DOX for 7 days were analyzed for NOTCH2 mRNA levels by qRT-PCR. F, H69/tet-MYCshRNA (left) and DMS53/tet-MYCshRNA (right) cells treated with vehicle or DOX for 7 days were analyzed for NOTCH2 mRNA levels by qRT-PCR. G, COR-L279/tet-MUC1shRNA (left) and H526/tet-MUC1shRNA (right) cells treated with vehicle or DOX for 7 days were analyzed for NOTCH2 mRNA levels by qRT-PCR. The results (mean ± SD of four determinations) are expressed as relative mRNA levels compared with that obtained for vehicle-treated cells (assigned a value of 1).

Year:

2025

Agents that target PD‐1 and PD‐L1 have been developed in the treatment of bladder cancer (BC). However, the diversity of immune cell infiltration in non‐muscle‐invasive BC (NMIBC) and the dynamics of the microenvironment as it progresses to muscle‐invasive/metastatic disease remains unknown. To assess tumor immune activity, hierarchical clustering was applied to 159 BC samples based on cellular positivity for the defined immune cellular markers (CD3/CD4/CD8/FOXP3/CD20/PD‐1/PD‐L1/LAG3/TIGIT), divided into two clusters. There was a “hot cluster” (25%) consisting of patients with a high expression of these markers and a “cold cluster” (75%) comprising those without. The expression of CD39, CD44, CD68, CD163, IDO1, and Ki67 was significantly higher in tumors in the hot cluster. Immunologically, high‐grade T1 tumors were significantly hotter, whereas tumors that had progressed to muscle invasion turned cold. However, a certain number of high‐grade NMIBC patients were in the cold cluster, and these patients had a significantly higher risk of disease progression. Using an externally available TCGA dataset, RB1 and TP53 alterations were more frequently observed in TCGA hot cluster; rather FGFR3 , KDM6A , and KMT2A alterations were common in TCGA cold/intermediate cluster. Analyses of recurrent tumors after BCG therapy revealed that tumor immune activity was widely maintained before and after treatment, and high FGFR3 expression was detected after recurrence in tumors initially classified into the cold cluster. Collectively, we revealed the dynamics of the tumor microenvironment in BC as a whole and identified candidate molecules as therapeutic targets for recurrent NMIBC, e.g., after BCG therapy.

Year:

2024

Introduction BRAF mutations in bladder cancer are rare. MEK inhibitors have excellent clinical benefits in the treatment of melanoma. Case presentation A 60‐year‐old male was diagnosed with muscle‐invasive bladder cancer and underwent total cystectomy and ileal conduit diversion. Despite 4 cycles of gemcitabine and cisplatin chemotherapy and 3 courses of pembrolizumab, the left obturator lymph node enlarged. Cancer multi‐gene panel testing confirmed the BRAF G469A mutation and trametinib was recommended. Three months after the initiation of trametinib (2 mg, qd), the left obturator lymph node shrank by more than 50%. The disease has remained stable for more than 18 months. Conclusion The present case indicates the potential of trametinib to treat mBUC patients with the BRAF G469A mutation in this setting.

Year:

2024

Collaborators (5)

Mark Long

Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Donald Kufe

Professor

Dana-Farber Cancer Institute

UNITED STATES
View details

Mototsugu Oya

-

JAPAN
View details

Henry Withers

Research Assistant Professor of Oncology

Roswell Park Comprehensive Cancer Center

UNITED STATES
View details

Kwok-Kin Wong

NYU Langone Medical Center

UNITED STATES
View details